Search

Thraustochytrids are emerging as a valuable biomass source for high-quality omega-3 polyunsaturated fatty acids (PUFAs), crucial for both human and animal nutrition. This research focuses on cultivating Schizochytrium limacinum SR21 using cost-effective agro-industrial by-products, namely sugarcane molasses (SCM), corn steep liquor (CSL), and residual yeast cream (RYC), to optimize biomass and lipid production through a comprehensive multistep bioprocess. The study involved optimization experiments in shake flasks and stirred-tank bioreactors, where we evaluated biomass, lipid content, and DHA yields. Shake flask optimization resulted in significant enhancements in biomass, lipid content, and lipid production by factors of 1.12, 1.72, and 1.92, respectively. In a 10 L stirred-tank bioreactor, biomass surged to 39.29 g/L, lipid concentration increased to 14.98 g/L, and DHA levels reached an impressive 32.83%. The optimal concentrations identified were 66 g/L of SCM, 24.5 g/L of CSL, and 6 g/L of RYC, achieving a desirability index of 0.87, aimed at maximizing biomass and lipid production. This study shows that agro-industrial by-products can be effective and low-cost substrates for producing lipids using thraustochytrids, offering a sustainable option for omega-3 PUFA production. The findings support future improvements in bioprocesses and potential uses of thraustochytrid biomass in food fortification, dietary supplements, nutraceuticals, and as vegan omega-3 sources.

It is widely known that mushrooms present several properties with applications in the medicinal and pharmaceutical sectors, including antimicrobial, immunomodulatory, antioxidant, hypotensive, neuroprotective, and anti-inflammatory activities. This article aims to review examples of the bioactive metabolites responsible for those activities, such as polysaccharides, phenols and polyphenols, terpenes, peptides, alkaloids, and steroids, which are produced by several relevant mushroom species. It also discusses their production through solid-state fermentation and submerged fermentation, as well as the processes of obtention of mushroom bioactive extracts and considerations on their stability aiming industrial applications. In addition, the article examines the patent landscape surrounding mushroom-derived bioactives, shedding light on the intellectual property history and innovations driving this field forward. Examples of recently deposited patents in the field are highlighted, as well as the main depositors. China and the United States are the major depositor countries in this field (52% and 35% of patents, respectively), and the principal compounds on the patents are polysaccharides and alkaloids. The article also provides insights into the current market landscape, showcasing mushroom-derived products in the pharmaceutical field available to consumers. From dietary supplements to skincare formulations, the market offerings reflect the growing interest in harnessing the health benefits of mushroom bioactives.